Nektar Therapeutics | NKTR - Despesa De Juros Sobre A Dívida





Despesa De Juros Sobre A Dívida Alterar Data
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
ALKERMES USD 27.55M 1.63M 2026-09
Amgen USD 653M 94.99B 2026-09
Baxter International USD 64M 14M 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 403M 4M 2026-09
Cara Therapeutics -89.64M 128.67M 2025-12
Cipla INR 167.4M 2.9M 2026-09
Dr.Reddys Laboratories INR 1.26B 198M 2026-06
Eisai JPY 1.96B 409M 2026-06
Eli Lilly USD 316M 201.3M 2026-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 5.59M 80K 2026-06
Incyte USD 605K 23K 2026-09
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.4M 493K 2026-06
Merck USD 525M 46M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 300K 2.6M 2026-09
Novartis USD 468M 6M 2026-09
Pfizer USD 662M 5M 2026-09
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.38B 466M 2026-09
Teva Pharmaceutical Industries USD 414M 219M 2026-09
Xencor USD 4.11M 3.24M 2026-09